Clinical Trial Update: Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 for HIV [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating autologous T cells genetically modified to disrupt CCR5 using zinc finger nucleases (SB-728) for HIV. The study status is listed as com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• SB-728

Snippet

Sponsor: University of Pennsylvania | Conditions: HIV, HIV Infections | Phase 1 | Status: COMPLETED